Citadel Advisors’s Travere Therapeutics TVTX Stock Holding History

Citadel Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.93M	Sell	199,600 -44,500	-18%	-$1.33M	﹤0.01%	4061
2025 Q4	$9.33M	Buy	244,100 +63,300	+35%	+$2.06M	﹤0.01%	3343
2025 Q3	$4.32M	Buy	180,800 +42,000	+30%	+$790K	﹤0.01%	4624
2025 Q2	$2.05M	Buy	138,800 +14,300	+11%	+$237K	﹤0.01%	5655
2025 Q1	$2.23M	Buy	124,500 +22,000	+21%	+$447K	﹤0.01%	5331
2024 Q4	$1.79M	Buy	102,500 +41,500	+68%	+$734K	﹤0.01%	5867
2024 Q3	$853K	Buy	61,000 +30,500	+100%	+$318K	﹤0.01%	7177
2024 Q2	$251K	Buy	30,500 +5,300	+21%	+$35.7K	﹤0.01%	9492
2024 Q1	$194K	Sell	25,200 -50,000	-66%	-$422K	﹤0.01%	10365
2023 Q4	$676K	Sell	75,200 -50,600	-40%	-$368K	﹤0.01%	7467
2023 Q3	$1.12M	Buy	125,800 +98,000	+353%	+$1.38M	﹤0.01%	6326
2023 Q2	$427K	Buy	27,800 +8,900	+47%	+$162K	﹤0.01%	8280
2023 Q1	$425K	Buy	18,900 +10,000	+112%	+$213K	﹤0.01%	8642
2022 Q4	$187K	Sell	8,900 -41,600	-82%	-$882K	﹤0.01%	10243
2022 Q3	$1.24M	Buy	50,500 +37,600	+291%	+$971K	﹤0.01%	6522
2022 Q2	$313K	Sell	12,900 -300	-2%	-$7.54K	﹤0.01%	9710
2022 Q1	$340K	Sell	13,200 -5,300	-29%	-$141K	﹤0.01%	10313
2021 Q4	$574K	Sell	18,500 -800	-4%	-$22.5K	﹤0.01%	9362
2021 Q3	$468K	Sell	19,300 -1,400	-7%	-$25.7K	﹤0.01%	10036
2021 Q2	$302K	Buy	20,700 +1,900	+10%	+$37.5K	﹤0.01%	11260
2021 Q1	$469K	Buy	+18,800	New	+$519K	﹤0.01%	9813
2020 Q4	–	Sell	-14,100	Closed	-$260K	–	11537
2020 Q3	$260K	Sell	14,100 -5,500	-28%	-$107K	﹤0.01%	8384
2020 Q2	$400K	Buy	+19,600	New	+$312K	﹤0.01%	7444
2019 Q4	–	Sell	-31,900	Closed	-$370K	–	9788
2019 Q3	$370K	Buy	+31,900	New	+$527K	﹤0.01%	7249
2019 Q2	–	Sell	-13,200	Closed	-$299K	–	9872
2019 Q1	$299K	Sell	13,200 -21,300	-62%	-$471K	﹤0.01%	7620
2018 Q4	$781K	Sell	34,500 -400	-1%	-$9.95K	﹤0.01%	5697
2018 Q3	$1M	Buy	34,900 +20,500	+142%	+$586K	﹤0.01%	5541
2018 Q2	$393K	Sell	14,400 -1,200	-8%	-$32K	﹤0.01%	6762
2018 Q1	$349K	Sell	15,600 -9,400	-38%	-$224K	﹤0.01%	6493
2017 Q4	$527K	Buy	25,000 +1,300	+5%	+$29.7K	﹤0.01%	5568
2017 Q3	$590K	Sell	23,700 -1,300	-5%	-$28.6K	﹤0.01%	5071
2017 Q2	$485K	Sell	25,000 -18,900	-43%	-$343K	﹤0.01%	5156
2017 Q1	$810K	Buy	43,900 +5,200	+13%	+$102K	﹤0.01%	4303
2016 Q4	$733K	Buy	38,700 +25,600	+195%	+$524K	﹤0.01%	4317
2016 Q3	$293K	Buy	13,100 +2,800	+27%	+$53.3K	﹤0.01%	5703
2016 Q2	$183K	Sell	10,300 -11,300	-52%	-$183K	﹤0.01%	5900
2016 Q1	$295K	Buy	21,600 +16,500	+324%	+$250K	﹤0.01%	5121
2015 Q4	$98K	Sell	5,100 -11,600	-69%	-$232K	﹤0.01%	6712
2015 Q3	$338K	Buy	16,700 +8,600	+106%	+$255K	﹤0.01%	5381
2015 Q2	$269K	Sell	8,100 -2,000	-20%	-$54.8K	﹤0.01%	5910
2015 Q1	$242K	Sell	10,100 -19,000	-65%	-$290K	﹤0.01%	5943
2014 Q4	$356K	Buy	29,100 +9,900	+52%	+$102K	﹤0.01%	5188
2014 Q3	$173K	Buy	+19,200	New	+$226K	﹤0.01%	5876

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors's TVTX Position: Q1 2026 in Review

Citadel Advisors increased its Travere Therapeutics (TVTX) stake by 531% in Q1 2026, buying an estimated $3.23M and bringing the position to 128,364 shares worth $3.81M. The position accounts for ﹤0.01% of the portfolio, ranked #4804.

Citadel Advisors first reported a position in TVTX in Q1 2014 and has held it in 47 quarters since. The position peaked at $37.1M in Q1 2022. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Citadel Advisors held 128,364 shares of Travere Therapeutics worth $3.81M as of Q1 2026.
Citadel Advisors bought 108,029 Travere Therapeutics shares in Q1 2026, an estimated $3.23M.
Travere Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4804 holding.
Citadel Advisors first reported a position in Travere Therapeutics in Q1 2014 and has held it in 47 quarters since.
Citadel Advisors's Travere Therapeutics position peaked at $37.1M in Q1 2022.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.